elbasvir/grazoprevir

DRUG5 trials

Conditions

BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaCryoglobulinaemic GlomerulonephritisDrug Interaction PotentiationHCVHepatitis CHepatitis C InfectionRefractory Liver Carcinoma

Phase 2

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

CompletedNCT02940496

M.D. Anderson Cancer CenterBCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection +8

Start: 2016-12-09End: 2023-08-09Updated: 2025-07-15

Phase 4

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

WithdrawnNCT03105349

Fundacion SEIMC-GESIDAHCV

Start: 2017-07-01End: 2018-02-28Updated: 2018-06-08

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

WithdrawnNCT03585101

University of California, Los AngelesHepatitis C

Start: 2018-08-31End: 2020-04-30Updated: 2018-08-07

Unknown Phase

Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy

NCT03433326

University of FlorenceCryoglobulinaemic Glomerulonephritis, Hepatitis C

Start: 2018-03-01End: 2018-12-31Target: 45Updated: 2018-02-14

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

CompletedNCT03706222

National Cheng-Kung University HospitalDrug Interaction Potentiation

Start: 2018-10-22End: 2019-02-25Updated: 2019-03-13

Related Papers

Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C